Table S2. Characteristics of advanced non-small cell lung cancer patients stratified for the presence of circulating tumor cells (CTC).

Characteristic	Total population (n=86, 100%)	Patients with CTC =0 (n=57, 66%)	Patients with CTC ≥1 (n=29, 34%)
Age, mean [sd]	62 [11]	62 [9]	62 [13]
Gender
Female	47 [55]	29 [51]	18 [62]
Male	39 [45]	28 [49]	11 [38]
ECOG1
PS 0	50 [58]	34 [60]	16 [55]
PS 1	29 [34]	18 [32]	11 [38]
PS 2	7 [8]	5 [9]	2 [7]
Smoking status: smoker	62 [72]	42 [74]	20 [69]
Stage
III	10 [12]	7 [12]	3 [10]
IV	76 [88]	50 [88]	26 [90]
Histology
Adenocarcinoma	73 [85]	49 [86]	24 [83]
Squamous cell	9 [10]	6 [10]	3 [10]
Other	4 [5]	2 [4]	2 [7]
Treatment line
First	60 [70]	40 [70]	20 [69]
Second	18 [21]	12 [21]	6 [21]
Third or higher	8 [9]	5 [9]	3 [10]
DNA aberrations2
None identified	39 [45]	27 [47]	12 [41]
EGFR	21 [24]	16 [28]	5 [17]
KRAS	9 [10]	6 [10]	3 [10]
ALK/ROS	7 [8]	2 [4]	5 [17]
BRAF	8 [9]	5 [9]	3 [10]
FGFR	1 [1]	0 [0]	1 [3]
Other	1 [1]	1 [2]	0 [0]
Tumor response3
Complete response	7 [8]	5 [9]	2 [7]
Partial response	36 [42]	29 [51]	7 [24]
Stable disease	13 [15]	11 [19]	2 [7]
Progressive disease	30 [35]	12 [21]	18 [62]
Therapy given
TKI	34 [40]	22 [39]	12 [41]
Chemotherapy	52 [60]	35 [61]	17 [59]
Progression free survival, months [range]	6 [0–55]	8 [0–55]	3 [0–37]
Overall survival, months [min–max]	11 [0–55]	13 [1–55]	5 [0–46]

¹, Eastern Cooperative Oncology Group Performance Score; ², molecular profiling performed in tissue biopsy of adenocarcinoma using a NGS multigene panel including TKI-targetable mutations, FISH for ALK, ROS1 and RET rearrangements and IHC for ALK expression on adenocarcinoma. Squamous cell were tested for FGFR1 amplifications; ³, Revised Response Evaluation Criteria In Solid Tumor v1.1; *, covariable was significantly different between treatment groups (P<0.05). IHC, immunohistochemistry; TKI, tyrosine kinase inhibitor.